Teacher Retirement System of Texas Sells 29,020 Shares of Certara, Inc. (NASDAQ:CERT)

Teacher Retirement System of Texas decreased its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 0.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,528,931 shares of the company's stock after selling 29,020 shares during the quarter. Teacher Retirement System of Texas owned about 2.80% of Certara worth $44,836,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. First Trust Advisors LP acquired a new stake in shares of Certara during the 4th quarter worth approximately $140,000. Illinois Municipal Retirement Fund grew its position in shares of Certara by 3.9% during the 1st quarter. Illinois Municipal Retirement Fund now owns 59,721 shares of the company's stock worth $591,000 after buying an additional 2,268 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Certara during the 4th quarter worth approximately $3,628,000. Proficio Capital Partners LLC acquired a new stake in shares of Certara during the 4th quarter worth approximately $148,000. Finally, Northern Trust Corp grew its position in shares of Certara by 14.0% during the 4th quarter. Northern Trust Corp now owns 877,010 shares of the company's stock worth $9,340,000 after buying an additional 108,038 shares during the period. Institutional investors and hedge funds own 73.96% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on CERT shares. Morgan Stanley started coverage on shares of Certara in a research report on Thursday. They issued an "equal weight" rating and a $16.00 price target for the company. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. JMP Securities reissued a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. KeyCorp lifted their price target on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Finally, Robert W. Baird lifted their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $15.71.

Certara Stock Down 1.4%

CERT traded down $0.16 during mid-day trading on Friday, reaching $11.33. 1,281,456 shares of the stock were exchanged, compared to its average volume of 1,459,372. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.78 and a current ratio of 2.78. The stock has a market capitalization of $1.84 billion, a PE ratio of 34.33 and a beta of 1.43. The company has a 50 day moving average price of $11.65 and a two-hundred day moving average price of $11.85. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $16.93.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 EPS. As a group, research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.